Novartis’s recent acquisition streak is pivoting the company toward new treatments that bear little resemblance to traditional drugs.
The Swiss company has spent nearly $15 billion in the past year to build its presence in cutting-edge areas of medical research, including gene therapy, or treatments that introduce new DNA into the body, and radiopharmaceuticals, which are drugs that carry radioactive particles to tumours for close-range radiotherapy. 543 more words
Still ranked No.10 globally among OTC marketers, Novartis has nevertheless been gradually disinvesting from the consumer healthcare market in recent years, as it pursues its plan to “become a more focused innovative medicines company”, according to CEO, Vas Narasimhan. 388 more words
AstraZeneca is to sell three of its respiratory drugs for $350m to the Swiss pharmaceutical group Covis Pharma, as the Anglo-Swedish group shifts its focus to new medicines to drive profit growth. 100 more words
Crónica de la jornada #ActivaTuMirada, organizada por la compañía Novartis.
